Dapagliflozin
Indication
In combination therapy for treating type 2 diabetes (NICE TA288)
NICE TA288 - Dapagliflozin in combination therapy for treating type 2 diabetes
Green (Restricted)
Brand:
Forxiga®
Nice TA:
288
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Dapagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if:
-
a sulfonylurea is contraindicated or not tolerated or
-
the person is at significant risk of hypoglycaemia or its consequences.
Dapagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option for treating type 2 diabetes.
The third recommendation, previously part of this guidance, has been updated and replaced by NICE’s technology appraisal guidance on dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
The LSCMMG recommends dapagliflozin as a 1st line ““gliflozin””.
Recommendation
LSCMMG Recommendation:
Green (Restricted)
Reason for decision:
Suitable for initiation in primary care in line with restrictions
Supporting documents: